- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02285140
Prevention of Infections in Cardiac Surgery (PICS)
September 20, 2023 updated by: Dominik Mertz, Hamilton Health Sciences Corporation
Prevention of Infections in Cardiac Surgery: a Cluster-randomized Factorial Cross-over Trial
There is clinical equipoise about the question of whether antibiotic prophylaxis should be given for a short period or an extended period of time as reflected by inconsistencies in major guidelines, current practices at Canadian centers, and as concluded in the three systematic reviews.
There also is clinical equipoise on whether the addition of vancomycin to routine cefazolin prophylaxis can further reduce s-SSI rates.
A short duration of combined antimicrobial prophylaxis can reduce side effects of exposure to antimicrobials such as infections with C. difficile or emergence of resistance, but may also reduce the incidence of s-SSIs.
The objective of the eventual full scale study is to determine whether adding vancomycin to cefazolin can reduce SSIs as well as whether short-term prophylaxis is as effective as long-term prophylaxis.
The rationale to conduct the proposed pilot study is to assess the feasibility to conduct this factorial cluster randomized cross-over trial, the adherence to the study protocol at each pilot site, the length of time to fill out the case report forms, and to get reliable estimates of event rates for sample size calculation for the main study
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
3000
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Dominik Mertz, MD, MSc
- Phone Number: 43952 (905) 521-2100
- Email: mertzd@mcmaster.ca
Study Contact Backup
- Name: Richard P Whitlock, MD, PhD
- Phone Number: 44091 905 527 4322
- Email: richard.whitlock@phri.ca
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Hamilton Health Sciences
-
Toronto, Ontario, Canada, M5B1W8
- St. Michael's Hospital
-
-
Quebec
-
Montréal, Quebec, Canada, H3T 1E2
- Jewish Hospital
-
Sherbrook, Quebec, Canada, J1H 5N4
- University of Sherbrook
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- All adult patients (≥18 years of age) undergoing open-heart surgery (sternotomy, including minimally-invasive surgical techniques).
Exclusion Criteria:
- Patients on antibiotics at the time of surgery.
- Previous enrollment in this trial.
- Known MRSA carriers. Beta-lactam allergy (IgE-mediated) precluding the use of cefazolin
- Participant in another study that may interfere with this trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cefazolin monotherapy, short course
One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered
|
administration as outlined
|
Experimental: Cefazolin monotherapy, long course
One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose).
|
administration as outlined
|
Experimental: Combination therapy, short course
One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered.
In addition, one dose of vancomycin 60-90min pre-op will be administered.
|
administration as outlined
administration as outlined
|
Experimental: Combination therapy, long course
One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose).
In addition, one dose of vancomycin 60-90min pre-op will be administered followed by 3 post-op doses every 12 hours (last dose 36 hours after first dose)
|
administration as outlined
administration as outlined
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients receiving antibiotics according to study protocol
Time Frame: 3 months post-surgery
|
Co-Primary outcome of pilot study
|
3 months post-surgery
|
Proportion of patients with complete follow-up, i.e. up to 90 days or death; goal >95%
Time Frame: 3 months post-surgery
|
Co-Primary outcome of pilot study
|
3 months post-surgery
|
Agreement of blinded outcome assessment based on information from the case report form
Time Frame: 3 months post-surgery
|
Co-Primary outcome of pilot study
|
3 months post-surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Deep incisional and organ/space sternal surgical site infection (NHSN/CDC)
Time Frame: 3 months post-surgery
|
Primary outcome of eventual full trial
|
3 months post-surgery
|
All types of sternal surgical site infection (superficial, deep, organ; NHSN/CDC)
Time Frame: 3 months post-surgery
|
Secondary outcome of eventual full trial
|
3 months post-surgery
|
Mortality
Time Frame: 3 months post-surgery
|
Secondary outcome of eventual full trial
|
3 months post-surgery
|
Clostridium difficile infection
Time Frame: 3 months post-surgery
|
Secondary outcome of eventual full trial
|
3 months post-surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Dominik Mertz, MD, MSc, Hamilton Health Sciences Corporation
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2015
Primary Completion (Estimated)
August 7, 2026
Study Completion (Estimated)
November 7, 2026
Study Registration Dates
First Submitted
November 4, 2014
First Submitted That Met QC Criteria
November 4, 2014
First Posted (Estimated)
November 6, 2014
Study Record Updates
Last Update Posted (Actual)
September 22, 2023
Last Update Submitted That Met QC Criteria
September 20, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PICS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thoracic Surgery
-
Maquet Cardiopulmonary GmbHNAMSARecruitingCardiac Surgery | Cardiopulmonary Bypass | Thoracic Surgery | Vascular SurgerySpain
-
Vanderbilt UniversityEdwards LifesciencesCompletedCardiac Surgery | Thoracic Surgery | Heart Surgery | Heart Transplant
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedCardiac Surgery | Cardiopulmonary Bypass | Thoracic SurgeryNetherlands
-
Federal University of Rio Grande do SulRecruiting
-
Association Pro-arteUniversity Hospital, GrenobleCompleted
-
Poovendran SaththasivamSuspendedThoracic SurgeryUnited States
-
Institut Mutualiste MontsourisFondation de l'Avenir; Paris cite university, 75006 Paris, FranceCompleted
-
Christopher McKeeTerminated
-
National Taiwan University HospitalCompletedThoracic SurgeryTaiwan
-
AstesCompletedThoracic SurgeryBelgium
Clinical Trials on Cefazolin
-
Abdul El-RabbanyNot yet recruitingOrthognathic Surgical Site Infection
-
B. Braun Medical Inc.ParexelCompleted
-
B. Braun Medical Inc.Terminated
-
University of Missouri-ColumbiaCompletedWounds and Injuries | Fractures, ClosedUnited States
-
Aultman Health FoundationCompletedWound InfectionUnited States
-
Stanford UniversityCompletedPre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery PatientsAortic Valve Disorder | Congenital Heart DiseasesUnited States
-
Phillip Brian SmithEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedSepsis | PrematurityBrazil
-
Brigham and Women's HospitalCompletedAntibiotic ProphylaxisUnited States
-
Chang Gung Memorial HospitalNot yet recruitingPeriprosthetic Joint InfectionTaiwan